齐鲁晚报.齐鲁壹点陈甜田通讯员孙善月徐大伟隋奎印 滨州市人民医院检验科顺利通过中国合格评定国家认可委员会(CNAS)ISO15189医学实验室认可初次现场评审，成为滨州市首家通过现场评审的实验室。 这标志着滨州市人民医院检验工作正式接轨国际"金标准"，检验质量与服务水平再上新台阶！ ISO15189，全称为《医学实验室—质量和能力的要求》，是由国际标准化组织发布的国际标准。该标准规定了医学实验室质量和能力的专用要求，旨在 推动实验室建立质量管理体系，并确保其具备持续提供技术上有效、管理上规范检验结果的能力，同时满足患者和医疗服务用户的临床需求。 获得ISO15189认可，意味着该医学实验室的管理体系和技术能力，符合这一国际金标准的要求，其出具的检验报告在全球范围内具有更高的可信度、有 效性和互认性。 此次评审由国内检验界知名专家组成评审团，中国人民解放军总医院第五医学中心李伯安担任评审组长，山东大学齐鲁第二医院检验医学中心公衍文、中 南大学湘雅医院钟白云、山东第一医科大学附属省立医院刘相东、广西中医药大学第一附属医院李明芬担任评审组成员。 评审组组长李伯安主持会议。 杨玉龙表示，滨州市人民医院检验科作为滨州市 ...

（来源：唐山劳动日报） 本报讯 （孙振、王彤）为大力弘扬志愿精神，推进医疗行业力量与志愿服务相互赋能，近日，唐山市 工人医院"健康送万家"医疗护理专家志愿服务队组织骨科、心脏康复科、神经内科等12个科室的专家们 前往路北区韩城镇东欢坨村，开展"冀益唐馨 医暖人心"送医下乡公益义诊活动。 活动现场，专家们各展所长，耐心地为乡亲们查体问诊并为他们提供专业的诊疗建议与贴心的健康指 导，医护志愿者们根据病情需要为部分村民提供免费心电图及血糖、血压检查，将三甲医院的优质医疗 服务送到老百姓家门口。 未来，工人医院将持续把医疗服务的"触角"延伸到最需要的地方，让志愿服务精神融入百姓看病就医的 每一个环节，用实际行动守护一方百姓的健康福祉。 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Views - The pharmaceutical sector underperformed the overall market, with a 0.39% decline in the biopharmaceutical sector compared to a 1.17% increase in the overall A-share market [32] - The TTM price-to-earnings ratio for the pharmaceutical sector is 38.51x, which is at the 84.35 percentile of the historical valuation over the past five years [32][37] Summary by Sections Market Performance - The overall A-share market increased by 1.17%, while the Shanghai and Shenzhen 300 index decreased by 0.62%. The biopharmaceutical sector saw a decline of 0.39% [32] - Among sub-sectors, chemical pharmaceuticals fell by 1.11%, while medical services dropped by 2.17%. Conversely, medical commercial and traditional Chinese medicine sectors saw increases of 4.26% and 0.89%, respectively [32] Fund Holdings Analysis - As of Q4 2025, the net asset value of pharmaceutical funds reached 358.4 billion, a decrease of 9.0% from the previous quarter [11] - The proportion of pharmaceutical holdings in all funds was 7.97%, down by 1.71 percentage points [16] - The largest sub-sectors by holdings were chemical preparations (37.5%) and other biological products (20.8%) [19] Key Company Earnings Forecasts and Investment Ratings - Major companies such as Mindray Medical (237 billion market cap, outperform rating), WuXi AppTec (293.6 billion market cap, outperform rating), and Aier Eye Hospital (105.4 billion market cap, outperform rating) are highlighted for their strong earnings forecasts [4] - The report lists several companies with outperform ratings, including New Industry, Huatai Medical, and others, with projected earnings growth over the next few years [4] Investment Strategy - The report emphasizes the importance of the CXO sector and recommends focusing on investment opportunities within this area due to its competitive advantages [41] - It also suggests continued recommendations for innovative drugs and the associated industry chain, with a specific investment portfolio for January 2026 including companies like Mindray Medical and WuXi AppTec [42][43]

Group 1 - The company expects a negative net profit for the fiscal year 2025, covering the period from January 1, 2025, to December 31, 2025 [1] - The company has communicated with its auditing firm regarding the performance forecast, and there are no discrepancies between the two parties [1] - The decline in operating income is attributed to market fluctuations and reforms in the DRG payment policy, leading to a decrease in revenue compared to the previous year [1] Group 2 - The company is implementing measures to adjust its business structure and improve operational efficiency, which has resulted in a narrowing of losses in the fourth quarter [1] - Despite these efforts, the total scale of operating income has not yet covered operational costs and period expenses [1]

3.业绩预告情况表 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000516 证券简称：国际医学 公告编号：2026-004 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本期业绩预计情况 1.业绩预告期间：2025年1月1日至2025年12月31日 2.业绩预告情况：预计净利润为负值 本次业绩预告是公司财务部门进行初步测算后的预计，未经审计机构审计。具体财务数据将在公司2025 年度报告中详细披露。敬请广大投资者注意投资风险。 特此公告。 西安国际医学投资股份有限公司董事会 二〇二六年一月二十七日 二、与会计师事务所沟通情况 本次业绩预告未经注册会计师预审计。公司就本次业绩预告与为公司提供年度审计服务的会计师事务所 签字注册会计师进行了预沟通，双方在本次业绩预告方面不存在分歧。 三、业绩变动原因说明 报告期内，公司受市场波动、DRG支付政策改革等行业动态调整影响，营业收入同比下降。公司采取 调整业务结构，实施降本增效等措施并持续改善经营成效，第四季度亏损幅度收窄，但营业收入总规模 尚未能覆盖运营成本和期间费用。 四、风险提示 ...

（来源：千龙网） 来自农工党界别的市政协委员、北京安贞医院双心医学中心主任刘梅颜建议，加强智慧医疗网络体系建 设，以远程医疗监测为基础，建立定期双心（心脏和心理）体检机制，加强双心医学学科建设。 刘梅颜长期工作在临床一线。她说，精神压力也会诱发心脏损伤和心理健康问题，"对双心健康问题的 长期监测和早期筛查发现尤其重要。"刘梅颜建议，可以根据心脏超声、心电图等数据，建立疾病数据 库，深入研究发病机制等，建立风险评估体系。在此基础上，专家团队要对存在健康风险的人群进行远 程咨询和心理疏导，形成个性化治疗方案。 刘梅颜还建议，集中北京双心优势资源，打通心血管和精神、心理、内分泌、睡眠等学科之间的通道， 加强双心医学学科建设，促进医院普遍开设双心门诊和双心病房。 ...

本报重庆电(记者沈靖然)"以前看病报销流程复杂，现在改革后方便多了，费用也更透明，我们老百姓 真是实实在在受益了。"日前，正在重庆市长寿区人民医院办理出院手续的赵先生说道。近年来，在医 疗保障改革进程中，长寿区医保局积极探索创新，构建"双向发力抓改革、数字赋能强监管、长效运行 促协同"的三维攻坚体系，大力推进医保支付方式改革，取得显著成效。 数字赋能方面，长寿区打通医保、卫健数据系统，开发"DRG三医协同监管"应用，实现智能监管三阶防 控，政策直达临床一线。协同机制上，建立"2+N"联席会议制度，医保、卫健部门联动监测整改，组建 专家库指导规范诊疗，推动医疗机构主动控费。 改革红利惠及民生，居民和职工医保次均费用低于全市平均，群众就医负担切实减轻。长寿区医保局相 关负责人表示，将持续深化改革，以创新举措提升基金效能，为医保高质量发展注入动力，助力健康中 国建设。 据介绍，该区将单病种管理嵌入DRG(诊断相关分组)付费体系，实现二级以上医院DRG全覆盖，基金占 比达84.16%，多项指标全市领先。改革中，区级医院示范引领，基层医疗机构全面覆盖，单病种结算 率5个月内从35%升至100%。 ...

Group 1 - The core viewpoint of the article indicates that International Medical (000516) is expecting significant losses in its financial performance for the year 2025, with projected net losses widening compared to the previous year [1][3] Group 2 - As of January 26, 2026, International Medical's stock closed at 5.16 yuan, down 0.96%, with a turnover rate of 3.28%, trading volume of 722,700 shares, and a transaction amount of 373 million yuan [1] - On January 26, the net inflow of main funds was 1.6254 million yuan, while retail investors showed a net inflow of 5.3559 million yuan, indicating mixed investor sentiment [1][3] Group 3 - The company forecasts a net profit loss attributable to shareholders of 295 million to 315 million yuan for 2025, which is an increase in losses compared to the previous year's loss of 254.1285 million yuan [1][3] - The expected operating revenue for 2025 is projected to be between 4.06 billion and 4.08 billion yuan, a decline from the previous year's revenue of 4.8154668 billion yuan, primarily due to market fluctuations and changes in DRG payment policies [1][3]

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Guo Ji Yi Xue (International Medicine), indicating a decline in revenue and profit for the third quarter of 2025 [2] - As of January 26, 2026, the stock price closed at 5.16 yuan, down 0.96%, with a turnover rate of 3.28% and a trading volume of 722,700 hands, amounting to a total transaction value of 373 million yuan [1] - The company reported a main revenue of 2.995 billion yuan for the first three quarters of 2025, a year-on-year decrease of 16.94%, and a net profit attributable to shareholders of -294 million yuan, down 38.45% year-on-year [2] Group 2 - In the third quarter of 2025, the company recorded a single-quarter main revenue of 961 million yuan, a year-on-year decline of 18.95%, and a net profit attributable to shareholders of -129 million yuan, a significant drop of 234.24% year-on-year [2] - The company has a debt ratio of 68.8%, with investment income of 20.7586 million yuan and financial expenses of 111 million yuan, resulting in a gross profit margin of 6.59% [2] - Over the past 90 days, two institutions have given a rating of "buy" for the stock, with an average target price of 5.5 yuan [3]

Core Viewpoint - Xinfang Pharmaceutical (002390) is actively involved in providing comprehensive health and elderly care services through its affiliated hospitals, indicating a strategic focus on the healthcare and eldercare sectors [1] Group 1: Company Initiatives - The company’s subsidiary, Guiyang Medical University Affiliated Baiyun Hospital, has established the Yikang Elderly Care Center, which aims to offer full-scale, professional, multi-level, and high-quality health and elderly care services for individuals who are disabled, semi-disabled, recovering from surgery, or have difficulty in daily living [1] - The company’s subsidiary, Guiyang Medical University Affiliated Wudang Hospital, has a long-term partnership with local nursing homes to provide medical, rehabilitation, and nursing services [1]